'Progression free survival pfs' presentation slideshows

FDA Review Team for Genasense (G3139)

Division of Oncology Drug Products Presentation NDA 21-649 Genasense (Oblimersen) for metastatic melanoma ODAC May 3, 2004. Project Management Nicholette Hemingway, MPH Medical Review Robert Kane, MD Ann Farrell, MD Statistical Review Peiling Yang, Ph.D.

675 views • 54 slides

Francisco Hernandez-Ilizaliturri MD Farhana Malik MBBS Myron Czuczman MD

Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with Non-Germinal center B-cell Phenotype is associated with a Higher response to Lenalidomide (L) or in Combination with Rituximab(R). Francisco Hernandez-Ilizaliturri MD Farhana Malik MBBS Myron Czuczman MD.

618 views • 43 slides

358 views • 16 slides

Blackwell KL et al. SABCS 2009;Abstract 61

Updated Survival Analysis of a Randomized Study of Lapatinib Alone or in Combination with Trastuzumab in Women with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab Therapy. Blackwell KL et al. SABCS 2009;Abstract 61. Introduction.

215 views • 7 slides

ABSTRACT

Individual Patient Data Analysis of Progression-Free versus Overall Survival as an Endpoint for Metastatic Colorectal Cancer in Modern Trials: Findings from the 16,700 Patient ARCAD Database

86 views • 1 slides

ABSTRACT

Individual Patient Data Analysis of Progression-Free versus Overall Survival as an Endpoint for Metastatic Colorectal Cancer in Modern Trials: Findings from the 16,700 Patient ARCAD Database

92 views • 1 slides